Tag - BRTX

Feature

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

BioRestorative Therapies (NASDAQ:BRTX) is a fully integrated regenerative medicine company with preclinical and Phase 2 clinical programs focused on conditioning the bodies’ regenerative potential to treat major...

March 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022

Tag - BRTX

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

Maxim starts BioRestorative Therapies at buy; PT $6

General

More